New Standard of Care Declared for First-Line Regimen in Multiple Myeloma

By adding daratumumab (Darzalex, Janssen Oncology), a CD38-specific IgG1 antibody, to conventional immunomodulatory drugs in patients with newly diagnosed, transplant-eligible multiple myeloma, the risk for disease progression or death at the end of four years was reduced 58% (hazard ratio, 0.42; P<0.001), according to results of the phase 3 PERSEUS trial. The results were presented as a late-breaker at the 2023 annual meeting of the American Society of Hematology (abstract LBA-1) and